Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
- Patel, VL
- Busch, EL
- Friebel, TM
- Cronin, A
- Leslie, G
- McGuffog, L
- Adlard, J
- Agata, S
- Agnarsson, BA
- Ahmed, M
- Aittomäki, K
- Alducci, E
- Andrulis, IL
- Arason, A
- Arnold, N
- Artioli, G
- Arver, B
- Auber, B
- Azzollini, J
- Balmaña, J
- Barkardottir, RB
- Barnes, DR
- Barroso, A
- Barrowdale, D
- Belotti, M
- Benitez, J
- Bertelsen, B
- Blok, MJ
- Bodrogi, I
- Bonadona, V
- Bonanni, B
- Bondavalli, D
- Boonen, SE
- Borde, J
- Borg, A
- Bradbury, AR
- Brady, A
- Brewer, C
- Brunet, J
- Buecher, B
- Buys, SS
- Cabezas-Camarero, S
- Caldés, T
- Caliebe, A
- Caligo, MA
- Calvello, M
- Campbell, IG
- Carnevali, I
- Carrasco, E
- Chan, TL
- Chu, ATW
- Chung, WK
- Claes, KBM
- Collaborators, GS
- Collaborators, E
- Cook, J
- Cortesi, L
- Couch, FJ
- Daly, MB
- Damante, G
- Darder, E
- Davidson, R
- de la Hoya, M
- Puppa, LD
- Dennis, J
- Díez, O
- Ding, YC
- Ditsch, N
- Domchek, SM
- Donaldson, A
- Dworniczak, B
- Easton, DF
- Eccles, DM
- Eeles, RA
- Ehrencrona, H
- Ejlertsen, B
- Engel, C
- Evans, DG
- Faivre, L
- Faust, U
- Feliubadaló, L
- Foretova, L
- Fostira, F
- Fountzilas, G
- Frost, D
- García-Barberán, V
- Garre, P
- Gauthier-Villars, M
- Géczi, L
- Gehrig, A
- Gerdes, A-M
- Gesta, P
- Giannini, G
- Glendon, G
- Godwin, AK
- Goldgar, DE
- Greene, MH
- Gutierrez-Barrera, AM
- Hahnen, E
- Hamann, U
- Hauke, J
- Herold, N
- Hogervorst, FBL
- Honisch, E
- Hopper, JL
- Hulick, PJ
- Investigators, K
- Investigators, H
- Izatt, L
- Jager, A
- James, P
- Janavicius, R
- Jensen, UB
- Jensen, TD
- Johannsson, OT
- John, EM
- Joseph, V
- Kang, E
- Kast, K
- Kiiski, JI
- Kim, S-W
- Kim, Z
- Ko, K-P
- Konstantopoulou, I
- Kramer, G
- Krogh, L
- Kruse, TA
- Kwong, A
- Larsen, M
- Lasset, C
- Lautrup, C
- Lazaro, C
- Lee, J
- Lee, JW
- Lee, MH
- Lemke, J
- Lesueur, F
- Liljegren, A
- Lindblom, A
- Llovet, P
- Lopez-Fernández, A
- Lopez-Perolio, I
- Lorca, V
- Loud, JT
- Ma, ESK
- Mai, PL
- Manoukian, S
- Mari, V
- Martin, L
- Matricardi, L
- Mebirouk, N
- Medici, V
- Meijers-Heijboer, HEJ
- Meindl, A
- Mensenkamp, AR
- Miller, C
- Gomes, DM
- Montagna, M
- Mooij, TM
- Moserle, L
- Mouret-Fourme, E
- Mulligan, AM
- Nathanson, KL
- Navratilova, M
- Nevanlinna, H
- Niederacher, D
- Nielsen, FCC
- Nikitina-Zake, L
- Offit, K
- Olah, E
- Olopade, OI
- Ong, K-R
- Osorio, A
- Ott, C-E
- Palli, D
- Park, SK
- Parsons, MT
- Pedersen, IS
- Peissel, B
- Peixoto, A
- Pérez-Segura, P
- Peterlongo, P
- Petersen, AH
- Porteous, ME
- Pujana, MA
- Radice, P
- Ramser, J
- Rantala, J
- Rashid, MU
- Rhiem, K
- Rizzolo, P
- Robson, ME
- Rookus, MA
- Rossing, CM
- Ruddy, KJ
- Santos, C
- Saule, C
- Scarpitta, R
- Schmutzler, RK
- Schuster, H
- Senter, L
- Seynaeve, CM
- Shah, PD
- Sharma, P
- Shin, VY
- Silvestri, V
- Simard, J
- Singer, CF
- Skytte, A-B
- Snape, K
- Solano, AR
- Soucy, P
- Southey, MC
- Spurdle, AB
- Steele, L
- Steinemann, D
- Stoppa-Lyonnet, D
- Stradella, A
- Sunde, L
- Sutter, C
- Tan, YY
- Teixeira, MR
- Teo, SH
- Thomassen, M
- Tibiletti, MG
- Tischkowitz, M
- Tognazzo, S
- Toland, AE
- Tommasi, S
- Torres, D
- Toss, A
- Trainer, AH
- Tung, N
- van Asperen, CJ
- van der Baan, FH
- van der Kolk, LE
- van der Luijt, RB
- van Hest, LP
- Varesco, L
- Varon-Mateeva, R
- Viel, A
- Vierstrate, J
- Villa, R
- von Wachenfeldt, A
- Wagner, P
- Wang-Gohrke, S
- Wappenschmidt, B
- Weitzel, JN
- Wieme, G
- Yadav, S
- Yannoukakos, D
- Yoon, S-Y
- Zanzottera, C
- Zorn, KK
- D'Amico, AV
- Freedman, ML
- Pomerantz, MM
- Chenevix-Trench, G
- Antoniou, AC
- Neuhausen, SL
- Ottini, L
- Nielsen, HR
- Rebbeck, TR
DOIAbstract
Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 3' region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001-c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c...
Add to ORKG